↓ Skip to main content

Anti-tumor effects of everolimus and metformin are complementary and glucose-dependent in breast cancer cells

Overview of attention for article published in BMC Cancer, March 2017
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (67th percentile)
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

twitter
5 X users
patent
1 patent

Citations

dimensions_citation
41 Dimensions

Readers on

mendeley
57 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Anti-tumor effects of everolimus and metformin are complementary and glucose-dependent in breast cancer cells
Published in
BMC Cancer, March 2017
DOI 10.1186/s12885-017-3230-8
Pubmed ID
Authors

Gerke Ariaans, Mathilde Jalving, Emma Geertruida Elisabeth de Vries, Steven de Jong

Abstract

Clinical efficacy of the mTOR inhibitor everolimus is limited in breast cancer and regularly leads to side-effects including hyperglycemia. The AMPK inhibitor and anti-diabetic drug metformin may counteract everolimus-induced hyperglycemia, as well as enhancing anti-cancer efficacy. We investigated the glucose-dependent growth-inhibitory properties of everolimus, metformin and the combination in breast cancer cell lines. The breast cancer cell lines MCF-7, MDA-MB-231 and T47D were cultured in media containing 11 mM or 2.75 mM glucose with 21% or 1% oxygen. Everolimus and metformin treated cells were subjected to cytotoxicity and clonogenic assays, western blotting, FACS and metabolic measurements. Everolimus was less effective in MCF7 cells under low glucose conditions compared to high glucose conditions (IC50 of >50 nM vs 29.1 ± 1.4 nM) in a short-term survival assay, while sensitivity of MDA-MB-231 and T47D cells to everolimus was lost under low glucose conditions. In contrast, metformin was more effective in low than in high glucose conditions in MCF7 (IC50 of 1.8 ± 1.2 mM vs >5 mM) and MDA-MB231 cells (1.5 ± 1.3 mM vs 2.6 ± 1.2 mM). Metformin sensitivity of T47D cells was independent of glucose concentrations. Everolimus combined with metformin additively inhibited cell survival, clonogenicity, mTOR signaling activity and mitochondrial respiration. These effects were not the result of enhanced autophagy or apoptosis induction. Similar results were observed under hypoxic conditions. Metformin-induced effects are additive to the anti-proliferative and colony inhibitory properties of everolimus through inhibition of mitochondrial respiration and mTOR signaling. These results warrant further in vivo investigation of everolimus combined with metformin as a putative anti-cancer therapy.

X Demographics

X Demographics

The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 57 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 57 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 9 16%
Researcher 7 12%
Student > Doctoral Student 5 9%
Student > Bachelor 5 9%
Student > Master 5 9%
Other 12 21%
Unknown 14 25%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 14 25%
Medicine and Dentistry 9 16%
Pharmacology, Toxicology and Pharmaceutical Science 6 11%
Agricultural and Biological Sciences 3 5%
Immunology and Microbiology 3 5%
Other 5 9%
Unknown 17 30%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 April 2021.
All research outputs
#6,766,018
of 24,927,532 outputs
Outputs from BMC Cancer
#1,696
of 8,825 outputs
Outputs of similar age
#100,436
of 314,050 outputs
Outputs of similar age from BMC Cancer
#26
of 125 outputs
Altmetric has tracked 24,927,532 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 8,825 research outputs from this source. They receive a mean Attention Score of 4.6. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 314,050 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 125 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.